Highlights

  • Shares climbed 21.95% to A$0.05 on 9 November 2026, lifting Market Capitalisation to about A$193.71 million.
  • Database lock for the XanaMIA pivotal trial was achieved on 20 October, with topline results now expected in mid-November.
  • The 247-patient trial compares Xanamem 10 mg with placebo over 36 weeks, using CDR-SB as the primary endpoint.
  • The study previously passed an independent Data Monitoring Committee safety and efficacy futility review before its final patient visit.

With topline data now only days away, Actinogen Medical (ASX:ACW) is heading into the most important readout in its history. A 21.95% gain to A$0.05 on 9 November 2026 puts the shares 21.95% higher over twelve months, as investors approach the results of XanaMIA, the company’s pivotal Alzheimer’s disease trial of its oral drug candidate Xanamem.

Database Lock Narrows the Timeline

Actinogen locked the XanaMIA database late on 20 October 2026 and announced the milestone the next day, narrowing earlier guidance of November to mid-November for topline results. The final participant visit took place in the United States on 22 September, and the trial is closed to recruitment.

The step matters because it freezes the data before analysis, but the company has not released any efficacy results yet.

What XanaMIA Is Testing

XanaMIA is a Phase 2b/3 randomised, double-blind, placebo-controlled study in mild-to-moderate Alzheimer’s disease. It enrolled 247 participants, 45% in Australia and 55% in the United States, who receive Xanamem 10 mg or placebo once daily for 36 weeks. The primary endpoint is the Clinical Dementia Rating Scale Sum of Boxes, known as CDR-SB.

Participants were selected using elevated blood pTau181, confirmed by a clinically validated blood test rather than amyloid PET or spinal fluid testing. Actinogen says this biomarker identifies a more progressive disease course, which may improve the trial’s power to detect a treatment effect, and mirrors the population from its earlier Phase 2a study.

Safety Checks and Open-Label Extension

The trial has passed an independent Data Monitoring Committee safety and efficacy futility review. Participants may also join the XanaMIA open-label extension, which began in March 2026, runs up to 25 months and gives all participants Xanamem 10 mg while assessing safety and a limited set of efficacy measures, including CDR-SB.

Future Outlook

Management says the focus is on releasing the results while planning streamlined paths to regulatory approval. The company has not specified a submission pathway. Xanamem remains investigational and is not approved by the FDA or any other regulator outside clinical trials. Actinogen has indicated that positive results would support targeting brain cortisol as a treatable part of Alzheimer’s biology.